Paratek Pharmaceuticals Performance
| PRTKDelisted Stock | USD 2.18 0.00 0.00% |
The company holds a Beta of 1.68, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Paratek Pharmaceuticals will likely underperform. Paratek Pharmaceuticals right now holds a risk of 0.0%. Please check Paratek Pharmaceuticals potential upside, as well as the relationship between the kurtosis and market facilitation index , to decide if Paratek Pharmaceuticals will be following its historical price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Paratek Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite quite persistent basic indicators, Paratek Pharmaceuticals is not utilizing all of its potentials. The current stock price mess, may contribute to short-term losses for the institutional investors. ...more
| Begin Period Cash Flow | 80.6 M | |
| Total Cashflows From Investing Activities | 14.8 M |
Paratek |
Paratek Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 218.00 in Paratek Pharmaceuticals on September 3, 2024 and sell it today you would earn a total of 0.00 from holding Paratek Pharmaceuticals or generate 0.0% return on investment over 90 days. Paratek Pharmaceuticals is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Paratek, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Paratek Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Paratek Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Paratek Pharmaceuticals, and traders can use it to determine the average amount a Paratek Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| PRTK |
Based on monthly moving average Paratek Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Paratek Pharmaceuticals by adding Paratek Pharmaceuticals to a well-diversified portfolio.
Paratek Pharmaceuticals Fundamentals Growth
Paratek Stock prices reflect investors' perceptions of the future prospects and financial health of Paratek Pharmaceuticals, and Paratek Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Paratek Stock performance.
| Return On Asset | -0.18 | |||
| Profit Margin | (0.35) % | |||
| Operating Margin | (0.25) % | |||
| Current Valuation | 345.3 M | |||
| Shares Outstanding | 57.32 M | |||
| Price To Earning | (5.49) X | |||
| Price To Sales | 0.86 X | |||
| Revenue | 150.79 M | |||
| EBITDA | (44.9 M) | |||
| Cash And Equivalents | 57.01 M | |||
| Cash Per Share | 1.03 X | |||
| Total Debt | 258.41 M | |||
| Debt To Equity | 3.20 % | |||
| Book Value Per Share | (3.52) X | |||
| Cash Flow From Operations | (66.14 M) | |||
| Earnings Per Share | (1.11) X | |||
| Total Asset | 172.54 M | |||
| Retained Earnings | (930.45 M) | |||
| Current Asset | 127.46 M | |||
| Current Liabilities | 21.75 M | |||
About Paratek Pharmaceuticals Performance
By examining Paratek Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Paratek Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Paratek Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts. Paratek Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 207 people.Things to note about Paratek Pharmaceuticals performance evaluation
Checking the ongoing alerts about Paratek Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Paratek Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Paratek Pharmaceuticals is not yet fully synchronised with the market data | |
| Paratek Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 150.79 M. Net Loss for the year was (63.57 M) with profit before overhead, payroll, taxes, and interest of 99.39 M. | |
| Paratek Pharmaceuticals currently holds about 57.01 M in cash with (66.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.03. | |
| Roughly 55.0% of the company shares are owned by institutional investors |
- Analyzing Paratek Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Paratek Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Paratek Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Paratek Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Paratek Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Paratek Pharmaceuticals' stock. These opinions can provide insight into Paratek Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Other Consideration for investing in Paratek Stock
If you are still planning to invest in Paratek Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Paratek Pharmaceuticals' history and understand the potential risks before investing.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |